Immediate administration of atorvastatin decreased the serum MMP-2 level and improved the prognosis for acute heart failure

Yamazaki, 2004, Circulating matrix metalloproteinase-2 is elevated in patients with congestive heart failure, Eur J Heart Fail, 6, 41, 10.1016/j.ejheart.2003.05.002 Wilson, 2002, Plasma matrix metalloproteinase and inhibitor profiles in patients with heart failure, J Card Fail, 8, 390, 10.1054/jcaf.2002.129659 Biolo, 2010, Episodes of acute heart failure syndrome are associated with increased levels of troponin and extracellular matrix markers, Circ Heart Fail, 3, 44, 10.1161/CIRCHEARTFAILURE.108.844324 Shirakabe, 2010, Clinical significance of matrix metalloproteinases in patients with acute heart failure, Int Heart J, 51, 404, 10.1536/ihj.51.404 Nakamura, 2011, Impact of early statin initiation on secondary prevention in Japanese patients with coronary artery disease, J Cardiol, 57, 172, 10.1016/j.jjcc.2010.11.004 Miura, 2010, Effects of statin and lipoprotein metabolism in heart failure, J Cardiol, 55, 287, 10.1016/j.jjcc.2010.02.003 Mozaffarian, 2005, The effects of atorvastatin (10mg) on systemic inflammation in heart failure, Am J Cardiol, 96, 1699, 10.1016/j.amjcard.2005.07.092 Chang, 2009, Effect of rosuvastatin on cardiac remodeling, function, and progression to heart failure in hypertensive heart with established left ventricular hypertrophy, Hypertension, 54, 591, 10.1161/HYPERTENSIONAHA.109.131243 Trochu, 2003, Preservation of NO production by statins in the treatment of heart failure, Cardiovasc Res, 60, 250, 10.1016/j.cardiores.2003.08.003 Ramasubbu, 2008, Experimental and clinical basis for the use of statins in patients with ischemic and nonischemic cardiomyopathy, J Am Coll Cardiol, 51, 415, 10.1016/j.jacc.2007.10.009 Krum, 2007, Statins and symptomatic chronic systolic heart failure: a post hoc analysis of 5010 patients enrolled in Val-HeFT, Int J Cardiol, 119, 48, 10.1016/j.ijcard.2006.07.106 Khush, 2007, Effect of high-dose atorvastatin on hospitalizations for heart failure: subgroup analysis of the treating to new targets (TNT) study, Circulation, 115, 576, 10.1161/CIRCULATIONAHA.106.625574 Nakaya, 2005, Pravastatin suppresses the increase in matrix metalloproteinase-2 levels after acute myocardial infarction, Int J Cardiol, 105, 67, 10.1016/j.ijcard.2004.12.024 Yasuda, 2007, Enhanced cardiac production of matrix metalloproteinase-2 and -9 and its attenuation associated with pravastatin treatment in patients with acute myocardial infarction, Clin Sci (Lond), 112, 43, 10.1042/CS20060110 Tziakas, 2004, Serum profiles of matrix metalloproteinases and their tissue inhibitor in patients with acute coronary syndromes. The effects of short-term atorvastatin administration, Int J Cardiol, 94, 269, 10.1016/j.ijcard.2003.05.013 Kjekshus, 2007, Rosuvastatin in older patients with systolic heart failure, N Engl J Med, 357, 2248, 10.1056/NEJMoa0706201 Tavazzi, 2008, Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial, Lancet, 372, 1231, 10.1016/S0140-6736(08)61240-4 Gheorghiade, 2005, Acute heart failure syndromes: current state and framework for future research, Circulation, 112, 3958, 10.1161/CIRCULATIONAHA.105.590091 Nieminen, 2005, Definition and epidemiology of acute heart failure syndromes, Am J Cardiol, 96, 5G, 10.1016/j.amjcard.2005.07.015 Crisby, 2001, Pravastatin treatment increases collagen content and decreases lipid content, inflammation, metalloproteinases, and cell death in human carotid plaques: implications for plaque stabilization, Circulation, 103, 926, 10.1161/01.CIR.103.7.926 Ikeda, 2000, Fluvastatin inhibits matrix metalloproteinase-1 expression in human vascular endothelial cells, Hypertension, 36, 325, 10.1161/01.HYP.36.3.325 Lefer, 2001, Vascular effects of HMG CoA-reductase inhibitors (statins) unrelated to cholesterol lowering: new concepts for cardiovascular disease, Cardiovasc Res, 49, 281, 10.1016/S0008-6363(00)00247-9 Aikawa, 1998, Lipid lowering by diet reduces matrix metalloproteinase activity and increases collagen content of rabbit atheroma: a potential mechanism of lesion stabilization, Circulation, 97, 2433, 10.1161/01.CIR.97.24.2433 Tousoulis, 2007, Statins in heart failure. Beyond the lipid lowering effect, Int J Cardiol, 115, 144, 10.1016/j.ijcard.2006.03.094 Gurjar, 1999, eNOS gene transfer inhibits smooth muscle cell migration and MMP-2 and MMP-9 activity, Arterioscler Thromb Vasc Biol, 19, 2871, 10.1161/01.ATV.19.12.2871 Hayashidani, 2002, Fluvastatin, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, attenuates left ventricular remodeling and failure after experimental myocardial infarction, Circulation, 105, 868, 10.1161/hc0702.104164 Ichihara, 2006, Pravastatin increases survival and suppresses an increase in myocardial matrix metalloproteinase activity in a rat model of heart failure, Cardiovasc Res, 69, 726, 10.1016/j.cardiores.2005.08.001 Daniels, 2007, Natriuretic peptides, J Am Coll Cardiol, 50, 2357, 10.1016/j.jacc.2007.09.021 Tsutamoto, 2007, Direct comparison of transcardiac difference between brain natriuretic peptide (BNP) and N-terminal pro-BNP in patients with chronic heart failure, Eur J Heart Fail, 9, 667, 10.1016/j.ejheart.2007.01.003 Gheorghiade, 2005, International Working Group on acute heart failure syndromes. Acute heart failure syndromes: current state and framework for future research, Circulation, 112, 3958, 10.1161/CIRCULATIONAHA.105.590091 Vrtovec, 2008, Atorvastatin therapy may reduce the incidence of sudden cardiac death in patients with advanced chronic heart failure, J Card Fail, 14, 140, 10.1016/j.cardfail.2007.10.013 Thambidorai, 2011, Impact of statin use on heart failure mortality, Int J Cardiol, 147, 438, 10.1016/j.ijcard.2010.08.016 Inokubo, 2001, Plasma levels of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 are increased in the coronary circulation in patients with acute coronary syndrome, Am Heart J, 141, 211, 10.1067/mhj.2001.112238